Such data may reasonably suggest to an oncologist that clinical trials of the HGF antagonist should test the hypothesis that it reduces metastasis in one or more tissue sites—either by reducing time to progression and/or improving overall survival, perhaps when used as a maintenance or adjuvant therapy18—rather than judging it solely on the basis of tumor shrinkage in progressive metastatic disease (see below). Here, HGF is linked to neoplasm.